Expanded RNAi Cardio Data Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY)

• Alnylam Pharmaceuticals recently presented new clinical and real-world data at the 2026 European Society of Cardiology Congress showing that its RNAi therapy AMVUTTRA (vutrisiran) maintained clinical benefits across ATTR amyloidosis patient groups, while investigational agent zilebesiran delivered enhanced blood pressure reductions in high-risk patients with uncontrolled hypertension.
• The breadth of outcomes data – from functional capacity and multisystem disease burden in ATTR-CM to 24-hour blood pressure control in hypertension – highlights how Alnylam’s RNAi platform could extend beyond rare disease into broader cardiovascular applications.
• We’ll now examine how this expanded evidence for vutrisiran’s broad ATTR-CM benefits and zilebesiran’s hypertension profile may reshape Alnylam’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Alnylam Pharmaceuticals Investment Narrative Recap

To own Alnylam, you have to believe that its RNAi platform can support a durable TTR amyloidosis franchise while expanding into broader cardiovascular disease, without overwhelming margins through pricing pressure or high spending. The new ESC data strengthen the clinical story for vutrisiran and zilebesiran, but they do not materially change the near term focus on AMVUTTRA net pricing, payer behavior and the risk that heavy reliance on the TTR franchise could magnify any commercial or competitive setback.

The 30 August ESC update is especially relevant because it follows Alnylam’s July guidance cut for 2026 net product revenue to US$4,700 million to US$5,100 million. Together, the guidance reset and fresh ATTR and hypertension data frame the next phase of the story: whether strengthened evidence for vutrisiran and zilebesiran can offset pricing and royalty headwinds and help justify continued high R&D and SG&A investment as management pushes beyond rare disease into higher prevalence indications.

Yet behind the strong clinical headlines, investors should be aware that…

Read the full narrative on Alnylam Pharmaceuticals (it’s free!)

Alnylam Pharmaceuticals’ narrative projects $9.0 billion revenue and $2.0 billion earnings by 2029.

Uncover how Alnylam Pharmaceuticals’ forecasts yield a $434.72 fair value, a 81% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue of about US$10,900 million and earnings of US$2,900 million by 2029, so if you are weighing that view against the new ESC data and the possibility that AMVUTTRA’s growth could slow outside rare disease, it is worth remembering that reasonable people can look at the same company and reach very different conclusions about its potential and its risks.

Explore 5 other fair value estimates on Alnylam Pharmaceuticals – why the stock might be worth just $230.00!

Form Your Own Verdict

Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.

• A great starting point for your Alnylam Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Alnylam Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Alnylam Pharmaceuticals’ overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don’t delay:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]